Metropolis Healthcare delivered exceptional Q4 FY26 results with consolidated net profit rising 74.67% YoY to ₹50.90 crore compared to the same period last year. According to reports from Business Standard, the company's revenue from operations increased 22.99% to ₹424.68 crore in Q4 FY26 over Q4 FY25. Profit before exceptional items and tax climbed 93.26% YoY to ₹69.65 crore during the quarter ended March 31, 2026. The company reported an exceptional loss of ₹10.69 crore during the quarter.
EBITDA stood at ₹108 crore in Q4 FY26, up 71.3% compared with ₹63 crore posted in Q4 FY25. As reported by Business Standard, EBITDA margin improved significantly to 25.4% in Q4 FY26 as against 18.5% in Q4 FY25. The company demonstrated strong operational metrics with patient volumes growing 11% YoY to 3.5 million and test volumes increasing 14% YoY to 7.6 million during the quarter. Revenue per Patient (RPP) improved 11% YoY to ₹1,210, while Revenue per Test (RPT) increased 8% YoY to ₹558, supported by favourable mix and higher contribution from specialised testing.
According to Business Standard, B2C revenues grew 20% YoY to ₹251 crore, driven by higher adoption of preventive and specialized testing, stronger digital engagement and hyperlocal marketing initiatives. B2B revenues increased 28% YoY to ₹174 crore, aided by strong client retention, hospital outsourcing opportunities, deeper partner relationships and improved service reliability. The company's full year FY26 consolidated net profit climbed 31.08% to ₹190.01 crore on 23.64% rise in revenue from operations to ₹1,645.84 crore over FY25.
As reported by Business Standard, the company's board declared 2nd interim dividend of ₹1 per equity share of face value ₹2 each for financial year 2025-26. The record date for dividend payment is Tuesday, May 19, 2026, with payment to be made within 30 days of declaration. Ameera Shah, promoter and executive chairperson, emphasized the company's focus on building a differentiated diagnostics platform driven by quality, innovation and customer trust. Surendran Chemmenkotil, managing director, highlighted the year's execution and operating transformation achievements, noting growth driven by healthy patient volumes and improved realisations without price increases in Q4.
